Piergiorgio Pettazzoni
Roche (Switzerland)(CH)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Computational Drug Discovery Methods, Protein Kinase Regulation and GTPase Signaling, Epigenetics and DNA Methylation, Renal cell carcinoma treatment
Most-Cited Works
- → Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function(2014)1,214 cited
- → Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer(2014)722 cited
- → Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer(2019)211 cited
- → 5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits(2015)153 cited
- → Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway(2019)148 cited
- → In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer(2016)148 cited
- → Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer(2017)128 cited
- → Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome(2015)104 cited
- → Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase(2024)93 cited
- → Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer(2015)82 cited